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ABSTRACT 
The murine mAb, K-1-21, recognizes a conformational epitope expressed on free Ig kappa 
light chains (FLCs) and also on cell membrane-associated FLCs found on kappa myeloma 
cells. This has led to the development of a chimeric version of K-1-21, MDX-1097, which is 
being assessed in a Phase II clinical trial for the treatment of multiple myeloma. The epitope 
recognized by K-1-21 is of particular interest, especially in the context that it is not expressed 
on heavy chain-associated light chains such as in an intact Ig molecule. Using epitope 
excision techniques we have localized the K-1-21 epitope to a region spanning residues 104-
110 of FLC. This short strand of residues links the variable and constant domains, and is a 
flexible region that adopts different conformations in FLC and heavy chain-associated light 
chain. We tested this region using site-directed mutations and found that the reactivity of K-
1-21 for FLC was markedly reduced. Finally, we applied in silico molecular docking to 
generate a model that satisfied the experimental data. Given the clinical potential of the Ag, 
this study may aid the development of next generation compounds that target the membrane 
form of FLC expressed on the surface of myeloma plasma cells. 
 







Therapeutic mAbs represent the largest class of biological agents with widespread use in 
oncology and autoimmunity. Each Ab is unique, and can function through many mechanisms 
such as inducing apoptosis, recruitment of effector cells and complement, and blocking 
interactions between receptors and ligands that are vital for activation of a target cell (Piggee, 
2008). Understanding the modes by which Abs interact with their cognate Ags is invaluable 
for future developments in Ab based therapeutics. Unfortunately, many Ab-Ag complexes 
fail to crystallise and their structures cannot be determined by high resolution X-ray 
diffraction. Complicating the matter further, most protein-binding Abs recognize targets 
through conformational epitopes, and conventional mapping techniques are limited (Caoili; 
Chen et al., 2009; Kiselar and Downard, 1999; Saul and Alzari, 1996). One such Ab is the 
murine mAb, K-1-21, which recognizes a conformational epitope on human free Ig kappa 
light chains (FLC), but does not recognise kappa light chains (LC) that are in association 
with Ig heavy chain (HC) such as in an intact Ig molecule (Boux et al., 1983; Raison and 
Boux, 1985).  
 
In humans, there are two isotypic variants of light chain (LC), kappa and lambda with 65% of 
B cells expressing the former (Barandun et al., 1976; Bradwell et al., 2008). LCs are 
composed of two beta-sheet rich Ig domains, the variable (V) and constant (C) domains that 
are connected by a short strand referred to as the ‘switch’ region (Schiffer et al., 1973). In an 
Ab molecule, the V domain of LC, in conjunction with the V domain of the associated heavy 
chain (HC), forms the Ag binding site. Diversity in the LC V domain is achieved by shuffling 
and recombination of individual germline gene segments, the variable and joining genes, 
during B cell development. The recombined V domain is then fused to the C domain which 
does not undergo recombination events (Abbas et al., 2007).  
 
During the process of Ab synthesis, LCs are produced in excess of HCs which causes the 
secretion of FLCs by plasma cells (Bradwell et al., 2008; Hopper and Papagiannes, 1986). 
FLCs exist in three forms: as covalent and non-covalent homodimers, formed via interactions 
of adjacent V and C domains, and as free monomers (Bradwell et al., 2008). High levels of 
FLC in serum can be indicative of an underlying plasma cell malignancy such as multiple 
myeloma (Bradwell et al., 2008; Mead et al., 2004). Furthermore, analysis with mAb K-1-21 




cells (Goodnow and Raison, 1985; Hutchinson et al., 2010; Walker et al., 1985). This has led 
to the development of a chimeric form of K-1-21, termed MDX-1097, that is currently 
undergoing assessment in a Phase II clinical trial for the treatment of multiple myeloma 
(Australian New Zealand Clinical Trials Registry Number: 12610000700033).  
 
Although early studies on the characterization of K-1-21 suggested that the Ab recognizes a 
conformational epitope located in the C domain of FLC (Raison and Boux, 1985), it remains 
to be elucidated how the mAb interacts with FLC but fails to recognize HC-associated 
forms of LC as found in an Ig molecule or an Fab fragment (Boux et al., 1983) (see 
Supplementary Fig. 1). In this study, we utilized a range of techniques to identify regions on 
FLC that may comprise the epitope recognized by K-1-21. Using the experimental data, we 
then applied in silico molecular docking to arrive at a suitable model for the Ab-Ag complex 






2. MATERIALS AND METHODS 
2.1 General reagents 
K-1-21 was produced on a fee for service basis by the Australian Commonwealth Scientific 
and Industrial Research Organization. FLC were purified from the urine of MM patients by 
ammonium sulfate precipitation as described previously (Raison and Boux, 1985). Monomers 
and dimers of FLC in these preparations were separated by size exclusion chromatography. 
 
2.2 K-1-21 affinity purification of in situ derived FLC peptides 
FLC peptides that had undergone proteolysis whilst being stored in urine were affinity 
purified by passage over a K-1-21 CNBr-activated Sepharose column (GE Biosciences). 
Purified peptides were subjected to two-dimensional electrophoresis. Briefly, samples were 
separated on a 3-10 pI immobilized gradient strip (BioRad), then size separated by SDS-
PAGE in a 4-12% Criterion XT gel (BioRad). Gels were stained with Flamingo fluorescent 
stain (BioRad) and imaged on a Pharos FX Plus Molecular Imager (BioRad). Spots 
containing relevant peptides were excised from the gel and trypsinised for nanoLC/MS-MS 
analysis which was performed by the Australian Proteome Analysis Facility (APAF), at 
Macquarie University, NSW. 
 
2.3 Epitope excision 
Epitope excision was performed essentially following the protocol described by Parker and 
Tomer (Parker and Tomer, 2000). Briefly, K-1-21 was immobilized on CNBr-Sepharose then 
incubated with 50 µg FLC for 2.5 h at room temperature. Unbound Ag was washed away 
and trypsin was added at a 1:20 w/w enzyme-substrate ratio. The digestion was carried out at 
37
o
C for 24 h with slow rotation. Trypsin and unbound peptides were removed by washing 
the columns with PBS prior to performing the MS analysis. In addition, FLC was incubated 
with trypsin in solution for use as a positive control for tryptic digestion. 
 
MALDI-MS was performed on a Voyager-DE STR (PerSeptive Biosystems) instrument 
equipped with a nitrogen laser (337 nm). The accelerating voltage was set at 20 kV and 
spectra were acquired by averaging data of 100 laser shots. Sepharose beads (15 L) were 
loaded on a C18 ZipTip (Millipore), washed three times with 0.1% TFA and bound peptides 
were eluted with 2 L of matrix solution. Only peptides in the detection range of 600-5000 




tryptic peptides with the same mass against a human or mouse protein database, allowing ±3 
Da error and up to 3 missed cleavage sites. 
 
2.4 Site-directed mutagenesis and expression of FLC constructs 
TheLC gene was amplified from JJN-3 cell line cDNA with forward and reverse primers 
comprising the sequence 5’-CACCATGGAAACCCCAGCG-3’ and 5’-
CTAGCACTCTCCCCTGTTG-3’ respectively. Using this as a template, internal mutagenic 
primers were designed (see Supplementary Table 2), and mutated constructs were amplified 
using LC specific primers with the various mutagenic primers. PCR products were cloned 
into the entry vector pENTR/D-TOPO then subcloned into the pT-Rex/DEST30 vector 
according to the manufacturer’s recommendations (Invitrogen). Truncated LC constructs 
were synthesized by GENEART, Germany. Purified expression plasmids were transfected 
into HEK-293 cells using the Freestyle Max expression system (Invitrogen). At Day 3, 
supernatants were collected and analysed by surface plasmon resonance. 
 
2.5 Testing the reactivity of K-1-21 to mutated FLC constructs 
The binding reactivity of K-1-21 to FLC constructs was assessed by surface plasmon 
resonance on a Biacore 2000 (GE Biosciences). K-1-21, polyclonal anti-LC (Sigma) and 
polyclonal anti-LC (isotype control; Sigma) were covalently coupled to the surface of a 
CM5 sensor chip (GE Biosciences). Cell supernatants from LC transfected HEK-293 cells 
were injected for 10 min at a flow rate of 20 μL/min, followed by a stabilization step for 10 
min. The surface was regenerated by injecting 10 mM glycine, pH 1.8 for 30 s at a flow rate 
of 100 μL/min. K-1-21 and anti-LC arbitrary response units for each FLC construct were 
standardized with reference to a FLC standard curve, then expressed as a percentage of the 
FLC control transfectant. 
 
2.6 Derivation of molecular models and docking studies 
A homology model of the K-1-21 Fv (VL and VH domains) was constructed using the 
Homology module of the Insight II program suite, version 98 (Accelrys, San Diego, CA, 
USA). Templates for the models were selected from the Protein Data Base (PDB) on the 
basis of sharing high amino acid similarities and CDRs of the same lengths and canonical 
structures to the sequences being predicted (Ramsland et al., 1999; Ramsland et al., 1997; 




12E8 for VL and 2RCS for VH (coordinates for the CDR3 of the HC were from 1BFV). The 
initial template-based K-1-21 Fv model was generated using the Modeller algorithm (Sali and 
Blundell, 1993), which was subjected to conjugate-gradient energy minimization until 
convergence to an energy gradient of 0.001 kcal/mol using the Crystallography and NMR 
System (Brunger et al., 1998). Harmonic restraints of 10.0 kcal/(mole Å
2
) were imposed on 
all main chain heavy atoms during the energy minimization simulations. 
 
A homology model of a covalent LC dimer was generated using procedures similar to those 
outlined above, however, the Discovery Studio package, version 2.5 (Accelyrs, USA) was 
used to prepare and optimize the model. Briefly, the V and C domains from the Del LC 
(PDB: 1B6D) were superimposed onto the 1.9 Å resolution structure of the Sea covalent LC 
dimer, PDB: 1JVK (Bourne et al., 2002; Terzyan et al., 2003). An interchain disulfide linkage 
was introduced linking the two LC monomers and the model was optimized by the Modeller 
algorithm and energy minimization within Discovery Studio. 
 
Rigid body molecular docking was performed with the ClusPro 2.0 algorithm 
(http://cluspro.bu.edu/) using K-1-21 as the receptor and Chain B of the FLC non-covalent 
dimer, PDB:1B6D, as the ligand (Comeau et al., 2007). Attraction regions were set on the 
LC comprising the residues 105-109 in the switch region, and the algorithm was run in Ab 
mode with the non-CDR regions masked in K-1-21. An appropriate model was chosen based 
on having a low energy ‘best fit’ score and whether LC switch residues made contact with 
K-1-21 CDRs (therefore satisfying the experimental data). The derived model was then 
optimized by the RosettaDock algorithm (http://rosettadock.graylab.jhu.edu/) which takes 
into account sidechain flexibility (Lyskov and Gray, 2008; Schueler-Furman et al., 2005). 
 
2.7 Kinetic analysis and determination of affinity constants 
For kinetic studies, we utilised an anti-Fc mAb capture method to determine affinity 
constants. The advantage of this approach is that it prevents the mAb surface from 
degradation between cycles due to the low pH in the regeneration buffer. As such, new mAb 
is captured onto the chip before each run. In brief, goat anti-mouse Ab (Sigma) was 
immobilized to the surface of a CM5 chip (GE Biosciences). K-1-21 at 10 μg/mL was 
injected for 1.5 min at 30 μL/min and the surface was stabilized for 10 min. This was 




concentrations ranging from 500 nM to 3.9 nM for 5 min. Dissociation for 15 min was 
followed by regeneration with 10 mM glycine pH 1.8 for 45 s at 100 μL/min flow rate. The 
data was fitted to a 1:1 Langmuir binding model using the BiaEvaluation 3.1 software (GE 
Biosciences) and the calculated kinetic values were regarded as acceptable at Chi
2
<2 and 




3.1 The K-1-21 epitope comprises part of the C domain of FLC 
We had previously identified a kappa Bence Jones protein (FLC) that had undergone 
proteolytic digestion whilst being stored in urine (presumably by proteases present in the 
sample). Analysis of this material using a K-1-21 affinity column yielded a number of LC 
fragments that were reactive with K-1-21. In order to identify these peptides, K-1-21 affinity 
purified LC fragments were subject to 2D electrophoresis. Two groups of peptides were 
present in the K-1-21 purified material; a monomeric FLC population migrating at 
approximately 25 kDa and peptides with apparent MW between 10-15 kDa (Fig. 1A). Of 
these lower MW peptides, four spots were selected for further analysis and following gel 
extraction and tryptic digestion, were analysed by LC/MS. 
 
Alignment of the tryptic peptides from the four samples revealed that the smallest peptide 
within which the epitope was retained yielded a sequence that commenced at R108 and 
terminated at K183 (Fig. 1B & Supplementary Table 1). This ruled out the C-terminal region 
from K183 onwards as being involved in the epitope. However, the N-terminal residue of this 
peptide could not be unequivocally assigned because the amino acid immediately preceding 
R108 is K107. Furthermore, in all LCs there is a primary amine at 103 (either lysine for 
JK1, JK2, JK3 and JK4 gene segments, or an arginine for the JK5 gene segment). Since the 
peptide samples were trypsinized before identification by LC/MS, cleavage at residues 103 
and 107 is unlikely to have yielded detectable peptides in the LC/MS analysis. In support of 
this, we note that a FLC peptide spanning residues 108-183 would have an estimated mass 
of 8kDa which is smaller than the actual mass of the peptide as shown by SDS-PAGE 
(between 10-15kDa; Fig. 1B). As such, it is likely that N-terminal residues preceding R108 





3.2 The switch region in FLC is protected by K-1-21 during trypsin digest 
Epitope excision was undertaken in order to further define the location of the epitope. The 
nature of this experiment relies on the protection of the antigenic determinant from enzymatic 
proteolysis when an Ag-Ab complex is formed. The success of such epitope protection assays 
is determined by the resistance of the Ab to digestion (Parker and Tomer, 2000). 
 
FLC bound to K-1-21 immobilised on Sepharose were digested with trypsin and, after 
washing, peptides bound to the Ab on the beads were identified by MALDI-MS and Mascot 
database search.  The smallest peptide (656.09 Da; LEIKR) was identified as part of the 
switch region (residues 104-108, the junction between V and C domains). This sequence is 
identical in both human and murine LC, thus it was possible that this peptide originated 
from either the Ab or the Ag, or both (Fig. 1B and Supplementary Fig. 2). However, 
exhaustive washing of the Sepharose-immobilized complex subsequent to proteolysis and 
prior to MALDI-MS, should eliminate any peptides originating from the Sepharose-bound K-
1-21. Furthermore, this peptide was not present in the mass spectrum of FLC digested in the 
absence of K-1-21 (see Supplementary Fig. 2), suggesting that the cleavage site between 
K107 and R108 was protected when FLC is bound to K-1-21. A slightly larger peptide 
(862.14 Da) was also observed to be bound to the immobilized Ab and was identified as an 
overlapping sequence, LEIKRTV (residues 104-110). This sequence is unique for human 
LC and probably resulted from non-specific cleavage after V110 (Fig. 1B and 
Supplementary Fig. 2). Again, this result suggested that epitope protection had taken place. 
Numerous other peptides were present at much lower peak intensities and were assigned as 
murine (K-1-21) HC and LC V region sequences (see Supplementary Fig. 2). 
 
3.3 Comparisons of LC structures reveal a conformational change at the switch region 
in FLCs 
The unique specificity of K-1-21 to FLC rather than HC-associated LC suggests there are 
conformational differences between the two forms of the molecule. We compared the 
structures of a FLC non-covalent dimer, PDB: 1B6D, with a HC-associated LC derived 
from the Fab, PDB: 2FGW. Interestingly, chain A of 1B6D dimer overlaid remarkably well 
with 2FGW LC indicating they are very similar in conformation (Fig. 2A). In contrast, the 
backbone of chain B in 1B6D dimer markedly deviated from the Fab LC in two places: at 




region, consisting of residues 165-171 (Fig. 2B). Fig. 3 highlights these regions in more 
detail. As shown, residues 104-109 and 165-171 of chain B of 1B6D dimer differ greatly in 
conformation in comparison to the corresponding regions found in 2FGW LC and chain A 
of 1B6D. Moreover, when looking at the position of the V and C domains in chain B, it 
becomes apparent that much of this conformational change can be attributed to a more acute 
angle formed between the two domains. As regions 104-109 and 165-171 in chain B are the 
only sites on FLC that are conformationally different to HC-associated LC, it reinforces 
the possibility that this region comprises the epitope bound by K-1-21. 
 
3.4 Mutation and truncation of FLC residues confirms the switch region as an essential 
component of the epitope 
Epitope excision and structural comparisons of LC highlighted the switch region and the 
adjacent loop as a putative epitope bound by K-1-21. In order to further define the epitope, 
we used site-directed mutagenesis and polypeptide truncation to identify critical residues 
involved in the binding of K-1-21 to FLC. The LC from the JJN3 myeloma cell line was 
cloned and the product expressed transiently in HEK-293 cells. Importantly, the expressed 
product retained the epitope bound by K-1-21 and also reacted with a polyclonal anti-LC Ab 
as determined by Biacore biosensor analysis. 
 
The LC constructs outlined in Table 1 were expressed and tested for reactivity with K-1-21 
and polyclonal anti-LC. Arbitrary response units of the recombinant proteins to K-1-21 and 
polyclonal anti-LC on the sensor chip were standardized with reference to a FLC standard 
curve then expressed as a percentage of the control full length recombinant LC (Table 1). 
The C domain construct showed reactivity to K-1-21 and polyclonal anti-LC of 43% and 
44%, respectively. These values were consistent with this fragment being approximately half 
the mass of the full length FLC, and thus resulting in values that are approximately half the 
full length FLC control. This interpretation was confirmed by the fact that the ratio of the 
reactivity of K-1-21 and the polyclonal Ab to this fragment (0.98) was similar to that of the 
full length FLC control. This confirmed that the K-1-21 epitope is retained in the peptide 
commencing at residue V104 and extending to the penultimate residue 214. To further define 
the K-1-21 epitope we generated and expressed another truncated LC construct beginning at 
residue K107 for comparison with the construct described above that contained the entire 




almost completely abolished the reactivity of K-1-21 to the truncated LC (K-1-21 to 
polyclonal anti-LC binding reactivity ratio of 0.12; Table 1) confirming the critical role of 
these residues in defining the K-1-21 epitope. 
 
Mutation of either E105 or T109 to alanine in the full length LC construct resulted in 
significant reduction in the ability of K-1-21 to recognize the polypeptide. The reactivity of 
K-1-21 was 36% and 28% for the E105A and T109A mutations respectively when compared 
to the non-mutated control. These mutations had significantly less effect on reactivity with 
polyclonal anti-LC (78% for E105A and 67% for T109A). Although these lower values 
could be attributed to low FLC expression levels by the transfected mutants, the large 
discrepancy in reactivity values between K-1-21 and anti-FLC suggest that part of the K-1-
21 epitope had been affected. This was highlighted in the FLC reactivity ratio of K-1-21 to 
the polyclonal anti-LC was reduced to 0.46 for E105A and 0.42 for T109A indicating that 
the effect of the mutations was largely restricted to the epitope recognized by K-1-21. 
 
It was noted that LCs derived from the JK3 segment contain an aspartic acid at 105 (found 
in approximately 5% of LC sequences; Kabat et al., 1992) rather than a glutamic acid.  As 
this residue was shown to be a key component of the epitope for K-1-21, it may have an 
impact on the clinical utility of MDX-1097 (the human chimeric equivalent of K-1-21) for a 
subset of myeloma patients. Therefore it was necessary to confirm that K-1-21 can still 
interact with LCs that have an aspartic acid at 105. Interestingly, mutation of E105 to 
aspartic acid resulted in enhanced binding of K-1-21 to FLC as indicated by a high 
reactivity ratio of 1.70 for K-1-21 versus the polyclonal anti-LC (Table 1). Thus we can 
conclude that MDX-1097 will retain reactivity to myeloma cells expressing LCs with D105. 
 
We also tested the role of the region around residues 165 to 171 by shuffling the native 
sequence DSKD (residues 167-170) to KDDS. For this construct the ratio of K-1-21 binding 
reactivity to anti-LC reactivity was 0.79 which indicated that the epitope was only partially 
affected (Table 1). To further define this region, we mutated Q166 to a proline in order to 
locally disrupt the conformation of the peptide chain. Interestingly, this mutation had no 
effect on the ability of K-1-21 to bind FLC (Table 1). Although this data suggests that the 




it is still possible this region may be part of the conformational epitope, but plays little role in 
the specificity of K-1-21. 
 
3.5 Model derivation and analysis 
To test the proposed role of the switch region in the K-1-21 epitope, we used in silico 
molecular docking to probe this region, and to derive an appropriate model for the K-1-21 – 
FLC complex. Initially we derived a structure of the K-1-21 Fv based on homology 
modelling. The K-1-21 Fv model was then docked onto the non-covalent FLC dimer 1B6D 
with the ClusPro 2.0 algorithm (Comeau et al., 2007). 
 
We found that K-1-21 could be docked onto the proposed epitope in Chain B of 1B6D. In this 
model, T109 is found buried deep in a hydrophobic binding pocket of K-1-21 formed by 
multiple tyrosine residues. In addition, a potential hydrogen bond (H-bond) occurs between 
T109 and V100 in K-1-21 HC. K107 side chain atoms interact via van der Waals forces with 
N32 and Y91 of K-1-21 LC, and the aromatic ring of Y104 in K-1-21 HC is found in close 
association with backbone atoms of K107. Main chain atoms between K107 and R108 form 
H-bonds with Y91 of K-1-21 LC. R108, in the proposed epitope, forms another H-bond with 
the side chain Y33 in K-1-21 HC, which is stabilized by van der Waals contacts between the 
side chains of Y101 in K-1-21 HC. Additionally, Y101 of K-1-21 HC also forms an H-bond 
with backbone atoms of K169 (Fig. 4A & B). 
 
In contrast to this model, K-1-21 failed to dock onto the same region in Chain A. As Chain A 
shares a similar conformation to HC-associated LC (Figs. 2 & 3), we also tested whether 
LC Fabs could be docked into the K-1-21 Fv. Similar to Chain A of 1B6D, none of these 
Fabs were able to dock via their switch regions to K-1-21. This further highlights the unique 
conformation of the proposed epitope in Chain B of 1B6D FLC.  
 
In addition, we attempted docking K-1-21 to a model of a covalent FLC dimer with both 
LCs in an extended conformation compared to Chain B of 1B6D. Again, the algorithm failed 
to dock K-1-21 Fv to either of the LC switch regions. This was an unexpected result, since 
K-1-21 has been shown to bind to covalently associated FLC dimers (Raison and Boux, 
1985). In this model, the switch region of Chain A is similar to HC-associated LC (and 




from the non-covalent dimer 1B6D. This is partly due to a more extended conformation of 
the V and C domains in the covalent dimer (Fig. 4C). Thus K-1-21 binding to a covalent LC 
may require a conformational change in the switch region inducing a more acute angle 
between the V and C domains. Access to the K-1-21 epitope on covalent LC is still 
predicted to be feasible since, in the model, one LC monomer displays a conformation closer 
to the acutely bent LC of the non-covalent dimer than to the extended LC associated with 
the HC in an Fab (Fig. 4C).  
 
Subsequently, we have measured the affinity of K-1-21 binding to monomers, covalent 
dimers and non-covalent dimers of FLC by plasmon resonance. We found that K-1-21 has 
higher affinity for non-covalent dimers than monomers and covalent dimers (Table 2). This 
indicates that the conformation of the K-1-21 epitope in non-covalent dimers is more 
accessible for binding to K-1-21. In addition, these data support the concept that induced fit 
plays a dominant role in K-1-21 binding to covalent LC dimers. This is highlighted by the 
finding that the rigid-body docking program was unable to generate complexes of the K-1-21 
Fv with the switch regions of the covalent LC dimer model. It is therefore possible that a 
small conformational change in the switch region may be necessary to allow the binding of 






Previous studies have shown that K-1-21 recognizes a conformational epitope located in the 
C domain of FLC. Interestingly, it does not recognize HC-associated LC (in the form of an 
Ab molecule or Fab), which suggests there are conformational differences between the two 
forms of the molecule (Raison and Boux, 1985). In this work, we initially used epitope 
excision with tryptic digestion to further define the region recognized by K-1-21. This 
yielded two overlapping peptides that were protected from tryptic digestion. These peptides 
encompassed residues L104 to V110 that make up the switch region connecting the V and C 
domain of LC. 
 
By analysing structures of HC-associated LC and FLC, we noted that the switch region 
and a spatially adjacent loop (residues 165-171) were conformationally different in the two 
forms of the molecule. Mutagenesis was then utilized to further examine the potential role of 
these regions in the epitope. It was found that alanine mutations at switch residues E105 and 
T109, reduced the reactivity of K-1-21 to FLC by more than 50% (based on the ratio of K-
1-21 reactivity to the polyclonal anti-LC reactivity). Furthermore, a partial switch deleted 
mutant (C domain commencing at K107) showed minimal binding to K-1-21, thus 
confirming that the switch region contains residues critical to the integrity of the epitope. To 
analyse the role of the adjacent loop, a shuffle mutant was expressed (residues 167-170 
shuffled from DSKD to KDDS) that showed a small but definitive reduction in the ability to 
bind to K-1-21. However, mutating Q166 to proline, in order to disrupt the peptide chain, 
showed no effect on K-1-21 reactivity. Together these results suggest this region is not 
critical to the epitope, but may provide a supporting role in the K-1-21 interaction with 
FLC. 
 
In the absence of an X-ray crystal structure, we derived a model of K-1-21 Fv based on 
previously solved structures of homologous mAbs. We next utilized the rigid-body molecular 
docking algorithm ClusPro 2.0 to determine whether the switch region could be 
accommodated in the binding site of K-1-21 (Comeau et al., 2007). A best-fit model was 
selected based on a combination of having low energy (highly ranked docking poses) and 
whether it was supported by the experimental data. The semi-rigid RosettaDock algorithm, 
which allows side chain flexibility (Schueler-Furman et al., 2005), was then used to further 




one of the key residues in the mutagenesis study, was found buried deep in the tyrosine-rich 
binding pocket of K-1-21, with an H-bond formed between the side chain of T109 and the 
backbone of V100 in the K-1-21 HC. Other important contact residues in the epitope were 
K107 and R108. Notably, these residues were protected by tryptic digest in the epitope 
excision experiment, which suggests they are located in the binding site of K-1-21. It is 
interesting to note that E105, which was thought to be a key component of the epitope based 
on the mutagenesis study, makes no contact with K-1-21 in the model. However, this residue 
is close to 107-109 (KRT residues) and may provide part of the scaffold for appropriate 
presentation of the contact residues to K-1-21. This is supported by the finding that a 
truncated form of LC, which begins at K107, and therefore does not have E105, fails to bind 
to K-1-21 indicating the loss of the epitope. Interestingly, K169 was found H-bonded with 
Y101 in K-1-21 HC. Seeing this interaction was mediated by main chain atoms rather than 
the side chain of K169, this suggests that a number of different residues may be substituted 
into this region without compromising the interaction with K-1-21. In support of this is the 
observation that various mutations in the loop comprising residues 166-170 showed little 
effect on K-1-21 binding. As such, it cannot be ruled out that this region does not play a 
definitive role in the epitope, however the interaction may be via an induced fit mechanism 
allowing for a range of different amino acids to be substituted into the peptide loop. 
 
In addition, we also tried docking K-1-21 Fv with HC-associated LCs, to which the mAb 
does not bind (Boux et al., 1983) (see Supplementary Fig. 1), and did not find any model in 
which K-1-21 bound to the LC via similar mechanisms. This further highlights the 
conformational nature of the epitope. Molecular docking also failed to find an appropriate 
model for K-1-21 bound to covalent FLC dimer. Experimental evidence shows that covalent 
FLCs can bind to K-1-21, albeit with lower affinity than non-covalent dimers. Combined 
with the docking results we suggest that conformational changes are required for covalent 
FLC dimers to interact with K-1-21. Perhaps the LC require a bent or acute conformation 
(with respect to the V and C domains) before they can bind K-1-21, which explains the 
unique specificity of this Ab for human FLC. 
 
In addition to soluble FLC, K-1-21 is highly specific for a cell surface determinant called 
KMA (kappa myeloma Ag) that consists of a complex of aggregated FLC bound to 




malignancies, and the chimeric version of K-1-21, MDX-1097, is currently being assessed in 
a Phase II clinical trial for multiple myeloma (Australian New Zealand Clinical Trials 
Registry Number: 12610000700033). Given KMA’s therapeutic potential as a tumour-
specific Ag, our findings are of interest in that the identified epitope region could be used for 
the rationale design of ‘next generation’ anti-KMA therapeutics. Developing new therapeutic 
agents targeting KMA is not straightforward given that LCs are also part of intact Ig 
molecules that are a major component of the B cell receptor that is expressed on most B cell 
subsets. Thus our determination of the K-1-21 epitope, which is unique to FLC rather than 
HC-associated LC, may be of great benefit in future screening or immunisation strategies 
for the development of anti-KMA compounds. 
 
In summary, we have utilized a number of experimental techniques to locate the epitope on 
FLC that is recognised by K-1-21. Using this information, we then applied in silico 
molecular docking to arrive at a suitable model for the K-1-21 mAb – FLC complex. In the 
absence of an empirically solved molecular structure, this approach may be suitable for the 
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Fig. 1. Identification of K-1-21 affinity purified FLC peptides. FLC that had undergone 
some proteolytic digestion in situ, was affinity purified by Sepharose-conjugated K-1-21. (A) 
The eluted fraction was subject to 2D electrophoresis then spots corresponding to fragments 
of LC (approximately 10-15 kDa) were cut out for analysis by nanoLC/MS-MS. (B) LC 
sequence showing the C domain and the switch region (residues 104-214). Underlined 
residues represent the smallest K-1-21 specific in situ derived peptide as identified by 
nanoLC/MS-MS. Residues in bold correspond to switch region fragments identified by 
epitope excision (see Table 1). Note residue 104 can be either a leucine or valine due to 
variability in LC joining gene segments. 
Fig. 2. Comparison of peptide backbones in FLC and HC-associated LC C domains. (A) C 
domain overlay of chain A 1B6D FLC (grey) with LC of 2FGW Fab (black). (B) C 
domain overlay of chain B 1B6D FLC (grey) with LC of 2FGW Fab (black). 
Fig. 3. Surface and ribbon diagrams of the proposed epitope region on LC. (A-C) Ribbon 
diagrams, (D-F) surface diagrams.  Chain B 1B6D dimer: A and D. Chain A 1B6D dimer: B 
and E. LC 2FGW Fab: C and F. Red highlighted residues constitute the switch region 
(residues 104-109) and blue highlighted residues are the adjacent loop (residues 165-171). 
Fig. 4. K-1-21 Fv bound to FLC model. (A) Surface and ribbon diagrams of the model. 
Magenta and cyan structures denote the K-1-21 HC and LC respectively. Grey denotes Chain 
B of 1B6D non-covalent dimer. (B) Key interactions taking place between K-1-21 Fv and the 
switch region of 1B6D non-covalent dimer. Atoms are colored by type (1B6D carbon, grey; 
K-1-21 HC carbon, magenta; K-1-21 LC carbon, cyan; nitrogen, blue; oxygen, red). H-bonds 
are shown as green dashed lines. (C) Carbon-alpha trace V domain overlays of Chain B LC 






Reactivity of recombinant FLC constructs to K-1-21 and polyclonal anti-LC. 
 
Construct Description Reactivity (% of LC control) 
 
Ratio* 
  K-1-21  anti-LC  
LC 
 
Full length LC 
control 
100 100 1 
VEIKRTV + 
C domain  
Residues 104 to 214 43 44 0.98 
KRTV +  
C domain 
 
Residues 107 to 214 5 43 0.12 
E105A 
 
E105 mutated to A 36 78 0.46 
T109A 
 
T109 mutated to A 28 67 0.42 
E105D E105 mutated to D 135 79 1.70 
KDDS DSKD (167-170) shuffled 
to KDDS 
67 85 0.79 
Q166P Q166 mutated to P 91 92 0.99 




 Table 2 
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